Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Logos Global Management LP

Q3 2023 · 13F-HR

Logos Global Management LPholdings as filed

Filed 2023-11-14 · accession 0001172661-23-003853

$749.5M
Reported value
56
Positions
2023-09-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
45258J102IMVTIMMUNOVANT INC$61.4M8.19%1,600,000CommonSOLE
45166A102IDYAIDEAYA BIOSCIENCES INC$60.7M8.10%2,250,000CommonSOLE
68062P106OLMAOLEMA PHARMACEUTICALS INC$46.2M6.17%3,743,875CommonSOLE
77313F106RCKTROCKET PHARMACEUTICALS INC$40.5M5.40%1,975,000CommonSOLE
23282W605CYTKCYTOKINETICS INC$36.8M4.91%1,250,000CommonSOLE
00973Y108AKROAKERO THERAPEUTICS INC$30.3M4.05%600,000CommonSOLE
03753U106APLSUSDAPELLIS PHARMACEUTICALS INC$28.5M3.81%750,000CommonSOLE
86366E106GPCRSTRUCTURE THERAPEUTICS INC$25.2M3.36%500,000CommonSOLE
03753U106APLSUSDAPELLIS PHARMACEUTICALS INC$24.7M3.30%650,000CALLSOLE
803607100SRPTSAREPTA THERAPEUTICS INC$24.2M3.23%200,000CommonSOLE
45258D105IMCRIMMUNOCORE HLDGS PLC$23.4M3.12%450,000CommonSOLE
45114M109ICOSAVAX INC$21.4M2.86%2,765,741CommonSOLE
26818M108DYNDYNE THERAPEUTICS INC$19.5M2.61%2,180,000CommonSOLE
48576A100KARUNA THERAPEUTICS INC$19.4M2.59%115,000CommonSOLE
64125C109NBIXNEUROCRINE BIOSCIENCES INC$16.9M2.25%150,000CommonSOLE
92790C104VRDNVIRIDIAN THERAPEUTICS INC$16.1M2.15%1,050,000CommonSOLE
98420N105XENEXENON PHARMACEUTICALS INC$15.4M2.05%450,000CommonSOLE
15678U128CERE1EURCEREVEL THERAPEUTICS HLDNG I$15.3M2.04%700,000CommonSOLE
G76279101ROIVROIVANT SCIENCES LTD$14.0M1.87%1,200,000CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$13.2M1.76%500,000CALLSOLE
60468T105MRTXEURMIRATI THERAPEUTICS INC$13.1M1.74%300,000CommonSOLE
03589W102ANNXANNEXON INC$12.5M1.67%5,300,000CommonSOLE
N44445109IMTXIMMATICS N.V$12.2M1.62%1,050,000CommonSOLE
25056L103DSGNDESIGN THERAPEUTICS INC$11.9M1.58%5,032,501CommonSOLE
01671P100ALLKGUSDALLAKOS INC$10.6M1.41%4,650,000CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$10.5M1.41%400,000CommonSOLE
76243J105RYTMRHYTHM PHARMACEUTICALS INC$9.2M1.22%400,000CommonSOLE
483497103KALVKALVISTA PHARMACEUTICALS INC$8.7M1.16%900,000CommonSOLE
92332V107VTYXUSDVENTYX BIOSCIENCES INC$7.8M1.04%225,000CommonSOLE
22663K107CRNXCRINETICS PHARMACEUTICALS IN$7.4M0.99%250,000CommonSOLE
38406L103GRACELL BIOTECHNOLOGIES INC$7.3M0.97%2,525,000CommonSOLE
20451W101CMPSCOMPASS PATHWAYS PLC$7.0M0.94%950,000CommonSOLE
76155X100RVMDREVOLUTION MEDICINES INC$6.9M0.92%250,000CommonSOLE
617760202MOR2MORPHOSYS AG$6.4M0.85%950,000CommonSOLE
760273102RPTXREPARE THERAPEUTICS INC$6.0M0.81%500,000CALLSOLE
374163103GERNGERON CORP$5.8M0.78%2,750,000CommonSOLE
N5749R1002GHMERUS N V$5.8M0.77%245,000CommonSOLE
00166B105ALXOALX ONCOLOGY HLDGS INC$4.8M0.64%1,000,000CommonSOLE
282559103ETNBGBP89BIO INC$4.8M0.64%310,000CommonSOLE
462260100IOVAIOVANCE BIOTHERAPEUTICS INC$4.5M0.61%1,000,000CALLSOLE
24661P807DCTHDELCATH SYS INC$4.2M0.56%1,044,444CommonSOLE
29337E102ELVNENLIVEN THERAPEUTICS INC$4.2M0.56%307,076CommonSOLE
04635X102CATBUSDASTRIA THERAPEUTICS INC$4.1M0.54%544,960CommonSOLE
834203309SLNOSOLENO THERAPEUTICS INC$3.7M0.49%125,000CommonSOLE
760273102RPTXREPARE THERAPEUTICS INC$3.6M0.48%300,000CommonSOLE
92539P101VERVE THERAPEUTICS INC$2.9M0.38%215,000CommonSOLE
G9TY5A101ZURAZURA BIO LTD$2.8M0.37%424,000CommonSOLE
00773J202SYREAEGLEA BIOTHERAPEUTICS INC$2.6M0.34%210,000CommonSOLE
02290A102AMBRX BIOPHARMA INC$1.3M0.18%115,000CommonSOLE
92673K108VIGLVIGIL NEUROSCIENCE INC$1.0M0.14%188,390CommonSOLE
449778109IOBTQIO BIOTECH INC$696,2960.09%493,827CommonSOLE
4525EP101VTLUSDIMMUNIC INC$619,1400.08%421,184CommonSOLE
52187K200CYPHLEAP THERAPEUTICS INC$488,8870.07%354,266CommonSOLE
90240B106TYRATYRA BIOSCIENCES INC$438,8770.06%31,872CommonSOLE
53000N108LIANYLIANBIO$417,2000.06%280,000CommonSOLE
67080N119NUVB/WSNUVATION BIO INC$6,6670.00%66,666CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.